home

Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal

TrendBristol-Myers Squibb2016-03-24 09:46 Read   143

Bristol-Myers Squibb ($BMY) has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D platform.

China detains 37 people linked to vaccine scandal: Xinhua

EVENTSxinhua2016-03-23 13:39 Read   125

Chinese police have detained 37 people linked to a vaccine scandal and are investigating three pharmaceutical companies, state news agency Xinhua reported on Wednesday.

WHO begs for $4 million to prepare for millions of Zika cases

RegulatorReuters2016-03-23 13:27 Read   93

Findings from a large observational study indicated no significant associations between selective serotonin reuptake inhibitors and increased risk for arrhythmia, myocardial infarction or stroke/transient ischemic attack in adults with depression.

Antidepressant use may not increase risk for cardiovascular outcomes

CommentsHealio2016-03-23 13:17 Read   120

Findings from a large observational study indicated no significant associations between selective serotonin reuptake inhibitors and increased risk for arrhythmia, myocardial infarction or stroke/transient ischemic attack in adults with depression.

BioMarin Heads to FDA With Mixed Data For Rare Disease Drug

TrendXconomy2016-03-23 13:05 Read   123

BioMarin Pharmaceutical had a setback in January when a gamble it had made on a Duchenne muscular dystrophy drug failed.

NICE backs Novartis' Entresto for heart failure

TrendPMLIVE2016-03-23 12:34 Read   95

The National Institute for Health and Care Excellence (NICE) has confirmed that Novartis' Entresto will be covered by the NHS for some patients with chronic heart failure (CHF).

Health Tip: Getting Enough Calories During Pregnancy

HealthHealth day2016-03-23 11:09 Read   98

Maintaining a healthy diet and an ideal weight are crucial during pregnancy.

Will Eli Lilly's 11th-hour regulatory gambit salvage or sink its Alzheimer's drug?

TrendFIERCE BIOTECH2016-03-23 10:58 Read   113

Eli Lilly ($LLY) didn't just surprise investors with its sudden about-face last week on its long-running Phase III program for the Alzheimer's drug solanezumab.

Merck wins high-stakes battle with Gilead over hep C patents

EVENTSSTAT2016-03-23 10:44 Read   109

A federal jury on Tuesday upheld the validity of two Merck patents in a high-stakes battle with Gilead Sciences, which may now have to pay royalties on some of the billions of dollars in sales generated by its wildly successful hepatitis C treatments.

FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death

RegulatorFDA2016-03-23 09:11 Read   103

In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications.

An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion

CommentsPLOS MEDICINE2016-03-22 14:29 Read   103

 The United States Food and Drug Administration (FDA) generally does not permit pharmaceutical manufacturers to promote their products for non-FDA-approved (“off-label”) indications.

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

RegulatorNICE2016-03-22 14:13 Read   166

Guanfacine prolonged‑release (Intuniv) is a non‑stimulant treatment for children and young people with attention deficit hyperactivity disorder (ADHD).